Covid biotech’s stock jumps af­ter pos­i­tive ear­ly PhI­II mon­o­clon­al an­ti­body da­ta re­veal

In­vivyd on Mon­day re­port­ed pos­i­tive ear­ly Phase III da­ta for its mon­o­clon­al an­ti­body de­signed to pre­vent symp­to­matic Covid-19 among im­muno­com­pro­mised in­di­vid­u­als, trig­ger­ing the biotech’s stock …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER